Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 4/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146430 | 0.91 | GHSR (0.41) | GHSRCYP17A1NAMPTBRS3RAB9A | |
| SCHEMBL25890385 | 0.88 | CYP11B1 (0.39) | GHSRCYP17A1NAMPTBRS3RAB9A | |
| SCHEMBL26318454 | 0.80 | NAMPT (0.57) | GHSRNAMPTRAB9A | |
| SCHEMBL31611248 | 0.80 | NAMPT (0.57) | GHSRNAMPTRAB9A | |
| SCHEMBL8346749 | 0.76 | GHSR (0.47) | GHSRRAB9AFAAH | |
| SCHEMBL14162121 | 0.74 | GHSR (0.42) | GHSRRAB9AFAAHMAPT | |
| SCHEMBL30759275 | 0.74 | NAMPT (0.43) | CYP17A1NAMPTBRS3RAB9ALATS1 | |
| SCHEMBL143257 | 0.74 | NAMPT (0.32) | NAMPTBRS3RAB9ALATS1MAPT | |
| SCHEMBL8344329 | 0.73 | KMT2A (0.50) | GHSRRAB9AFAAH | |
| SCHEMBL3489715 | 0.73 | TSHR (0.44) | GHSRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GHSR 3672/4885CYP17A1 667/4885NAMPT 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.